Benzodiazepine Withdrawal Protocol for Concurrent Benzodiazepine and Cocaine Use

Direct Recommendation

For a patient taking a short-acting benzodiazepine as prescribed who also uses cocaine, first stabilize cocaine use with behavioral interventions while maintaining the benzodiazepine at the current dose, then initiate a gradual benzodiazepine taper at 10–25% of the current dose every 1–2 weeks, with mandatory specialist referral due to the co-occurring substance use disorder. 1

Critical Safety Framework

Abrupt benzodiazepine discontinuation can cause seizures and death—never stop suddenly, regardless of cocaine use status. 1, 2 Benzodiazepine withdrawal carries greater risks than opioid withdrawal and must always be conducted gradually. 1

The combination of benzodiazepine dependence and active cocaine use creates compounded risks:

Cocaine withdrawal can mimic or worsen benzodiazepine withdrawal symptoms (anxiety, agitation, insomnia) 1
Seizure threshold is lowered by both cocaine use and benzodiazepine withdrawal 1
Polysubstance use predicts higher taper failure rates 3

Mandatory Specialist Referral

Patients with co-occurring substance use disorders—including cocaine use—should be referred to a specialist immediately rather than managed in primary care alone. 1 This is a non-negotiable guideline recommendation. Specialist involvement should include addiction medicine or psychiatry with expertise in dual diagnosis. 1

Pre-Taper Assessment Requirements

Before initiating any benzodiazepine taper, document:

Current benzodiazepine: Specific agent (alprazolam, lorazepam, etc.), total daily dose, dosing schedule, and duration of use 1
Cocaine use pattern: Frequency, route, quantity, last use, and any prior withdrawal attempts 1
Seizure history: Any prior withdrawal seizures from benzodiazepines, alcohol, or cocaine require immediate specialist management 1
Psychiatric comorbidities: Screen for depression, anxiety disorders, panic disorder, and suicidal ideation 1
Other substance use: Check prescription drug monitoring program (PDMP) for all controlled substances; assess for alcohol, opioids, and other CNS depressants 1
Social stability: Housing, support system, ability to attend frequent appointments 3

Recommended Tapering Protocol

Step 1: Stabilize Cocaine Use First

Do not initiate benzodiazepine tapering while cocaine use is active and unstable. 3 The evidence from bridge clinic protocols demonstrates that attempting simultaneous withdrawal from multiple substances results in high loss-to-follow-up rates (57%) and taper failure. 3

Engage the patient in intensive outpatient substance use treatment or residential care for cocaine use disorder 1
Maintain the benzodiazepine at the current prescribed dose during this stabilization phase 1
Offer evidence-based psychological therapies (cognitive-behavioral therapy, contingency management) for cocaine use disorder 1
Establish at least 2–4 weeks of cocaine abstinence or significant reduction before beginning benzodiazepine taper 3

Step 2: Convert Short-Acting Benzodiazepine to Diazepam (Optional but Preferred)

For patients on alprazolam or lorazepam, converting to diazepam provides more protection against seizures and smoother withdrawal due to its longer half-life. 1, 4, 5

Conversion ratios:

Alprazolam 1 mg = Diazepam 10 mg 1
Lorazepam 1 mg = Diazepam 10 mg 1

Perform a gradual cross-taper over 1–2 weeks:

Reduce alprazolam/lorazepam by 25% while introducing equivalent diazepam 1
Continue until fully converted to diazepam 1

Exception: Elderly patients or those with hepatic dysfunction should remain on lorazepam or oxazepam rather than converting to diazepam due to lower fall and sedation risk. 1

Step 3: Initiate Gradual Benzodiazepine Taper

Standard taper schedule: Reduce by 10–25% of the current dose (not the original dose) every 1–2 weeks. 1, 2

Example for a patient on alprazolam 2 mg/day:

Weeks 1–2: Reduce to 1.5 mg/day (25% reduction) 2
Weeks 3–4: Reduce to 1.1–1.2 mg/day (20–25% of current dose) 2
Weeks 5–6: Reduce to 0.8–0.9 mg/day 2
Continue reducing by 10–25% of the current dose every 1–2 weeks 2

For patients on benzodiazepines >1 year: Slow the taper to 10% of the current dose per month to minimize withdrawal symptoms. 1, 2

Realistic timeline: This taper will require a minimum of 6–12 months, and possibly longer. 1, 2 Pauses in the taper are acceptable and often necessary when withdrawal symptoms emerge. 1

Monitoring Requirements

Follow up at least monthly during the taper, with more frequent contact (weekly or twice-weekly) during difficult phases. 1, 2

At each visit, assess:

Withdrawal symptoms: Anxiety, tremor, insomnia, sweating, tachycardia, headache, weakness, muscle aches, nausea, confusion, seizures 1
Cocaine use status: Urine drug screens, self-report, collateral information 3
Psychiatric symptoms: Depression, panic attacks, suicidal ideation 1
Functional status: Ability to maintain daily activities, work, relationships 1
Medication adherence: Verify patient is taking prescribed doses, not escalating 1

Clinically significant withdrawal symptoms signal the need to slow the taper rate or pause entirely. 1, 2 Hold at the current dose for 2–4 weeks, optimize supportive measures, then resume at a slower rate. 1

Pharmacological Adjuncts to Ease Withdrawal

First-Line: Gabapentin

Gabapentin is the preferred adjunct to mitigate benzodiazepine withdrawal symptoms. 1, 2, 6

Starting dose: 100–300 mg at bedtime or three times daily 1, 2
Titration: Increase by 100–300 mg every 1–7 days as tolerated 1, 2
Target dose: Typically 900–1800 mg/day in divided doses 1
Caution: Adjust dose in renal insufficiency; monitor for dizziness and sedation 1

Second-Line Options

Carbamazepine: May assist discontinuation but can affect alprazolam metabolism; use with caution 1, 6, 4
Pregabalin: Has shown potential benefit in facilitating tapering 1, 6
SSRIs (paroxetine, sertraline): May help manage underlying anxiety during tapering but do not directly treat withdrawal 1, 6
Trazodone 25–200 mg: For short-term insomnia management without abuse potential 1

Do not substitute another benzodiazepine or Z-drug (zolpidem, zaleplon) as these carry similar dependence risks. 1

Non-Pharmacological Interventions (Mandatory)

Cognitive-behavioral therapy (CBT) during the taper significantly increases success rates and should be incorporated. 1, 2, 4, 5 CBT specifically targeting avoidance behaviors (e.g., reliance on benzodiazepines for anxiety, cocaine use for energy) improves taper success and reduces relapse risk. 1

Additional supportive measures:

Mindfulness and relaxation techniques 1
Sleep hygiene education 1
Exercise and fitness training 1
Patient education about benzodiazepine risks and benefits of tapering 1, 6
Recovery coaching or peer support 3

Managing Cocaine Use During Benzodiazepine Taper

Cocaine use disorder requires concurrent behavioral treatment throughout the benzodiazepine taper. 1, 3

Evidence-based interventions for cocaine use disorder:

Contingency management: Provides tangible rewards for negative urine drug screens 1
Cognitive-behavioral therapy: Addresses triggers, coping skills, and relapse prevention 1
Community reinforcement approach: Restructures environment to support abstinence 1

No FDA-approved medications exist for cocaine use disorder, but consider:

Topiramate or disulfiram (off-label, modest evidence) 1
N-acetylcysteine (investigational, may reduce cravings) 1

If the patient resumes heavy cocaine use during the benzodiazepine taper, pause the taper and re-stabilize cocaine use before proceeding. 3

When to Pause or Slow the Taper

Pause the taper and hold at the current dose if:

Severe withdrawal symptoms emerge (tremor, confusion, hallucinations, seizures) 1, 2
Suicidal ideation or severe depression develops 1
Functional decline occurs (cannot maintain daily activities) 1
Cocaine use escalates or relapse occurs 3

After pausing for 2–4 weeks and optimizing supportive measures, restart the taper at a slower rate (e.g., 10% per month instead of 10–25% every 1–2 weeks). 1, 2

Critical Pitfalls to Avoid

Never taper too quickly: Rapid tapers result in only 24% completion rates. 1 The goal is durability, not speed. 1, 2
Never reduce by a percentage of the original dose: Always reduce by a percentage of the current dose to prevent disproportionately large final reductions. 1, 2
Never abandon the patient: Even if tapering is unsuccessful, maintain the therapeutic relationship and consider maintenance therapy. 1
Never ignore cocaine use: Attempting benzodiazepine withdrawal while cocaine use is active and unstable leads to high failure rates. 3
Never prescribe additional CNS depressants: Avoid adding opioids, alcohol, or other sedatives during the taper. 1

Expected Outcomes After Successful Withdrawal

Improved psychomotor and cognitive functioning, particularly in memory and daytime alertness. 2, 4 Improvement in anxiety symptoms and general well-being is maintained during both the taper and follow-up phases. 2 Reduced fall risk, improved mobility, and restoration of functional independence, especially in elderly patients. 2

However, a considerable proportion of patients may temporarily take benzodiazepines again, and some need other psychotropic medication. 5 Long-term outcome is improved by careful pharmacological and psychological handling of withdrawal and post-withdrawal phases. 5

Summary Algorithm

Assess: Document benzodiazepine use, cocaine use pattern, seizure history, psychiatric comorbidities, and social stability 1
Refer: Immediate specialist referral for co-occurring substance use disorder 1
Stabilize cocaine use: Engage in intensive behavioral treatment; maintain benzodiazepine at current dose 3
Convert to diazepam (optional): If on alprazolam/lorazepam, perform gradual cross-taper 1, 4
Initiate taper: Reduce by 10–25% of current dose every 1–2 weeks (or 10% per month if >1 year use) 1, 2
Add gabapentin: Start 100–300 mg TID, titrate as tolerated 1, 2
Integrate CBT: Mandatory throughout taper 1, 4
Monitor closely: At least monthly, more frequently during difficult phases 1, 2
Pause if needed: Hold taper for 2–4 weeks if withdrawal symptoms, cocaine relapse, or functional decline occurs 1, 3
Expect 6–12 months minimum: Realistic timeline for safe, durable taper 1, 2

What is a safe, medically supervised tapering protocol for a patient who is taking a short‑acting benzodiazepine (e.g., alprazolam or lorazepam) as prescribed and also using cocaine, and wishes to discontinue both substances?

Help us tailor your experience